Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Traws Pharma Inc’s stock clocked out at $1.48, down -13.95% from its previous closing price of $1.72. In other words, the price has decreased by -$13.95 from its previous closing price. On the day, 0.58 million shares were traded.
Ratios:
To gain a deeper understanding of TRAW’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.81 and its Current Ratio is at 1.81. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Ladenburg Thalmann on March 01, 2022, initiated with a Buy rating and assigned the stock a target price of $7.
On May 18, 2021, Guggenheim started tracking the stock assigning a Buy rating and target price of $4. H.C. Wainwright reiterated its Buy rating for the stock on March 01, 2018, while the target price for the stock was revised from $6 to $7.50.
Stock Price History:
Over the past 52 weeks, TRAW has reached a high of $19.44, while it has fallen to a 52-week low of $0.97. The 50-Day Moving Average of the stock is -10.44%, while the 200-Day Moving Average is calculated to be -70.12%.
Shares Statistics:
A total of 5.08M shares are outstanding, with a floating share count of 4.52M. Insiders hold about 18.85% of the company’s shares, while institutions hold 20.34% stake in the company.
